- Home
- PSTV vs COEP Comparison
PSTV vs COEP Comparison
Compare PSTV & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- COEP
- Stock Information
- Founded
- PSTV 1996
- COEP 2017
- Country
- PSTV United States
- COEP United States
- Employees
- PSTV N/A
- COEP N/A
- Industry
- PSTV Medical/Dental Instruments
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSTV Health Care
- COEP Health Care
- Exchange
- PSTV Nasdaq
- COEP Nasdaq
- Market Cap
- PSTV 6.3M
- COEP 7.3M
- IPO Year
- PSTV N/A
- COEP N/A
- Fundamental
- Price
- PSTV $1.14
- COEP $0.14
- Analyst Decision
- PSTV Strong Buy
- COEP
- Analyst Count
- PSTV 2
- COEP 0
- Target Price
- PSTV $13.50
- COEP N/A
- AVG Volume (30 Days)
- PSTV 90.1K
- COEP 961.2K
- Earning Date
- PSTV 11-14-2024
- COEP 11-13-2024
- Dividend Yield
- PSTV N/A
- COEP N/A
- EPS Growth
- PSTV N/A
- COEP N/A
- EPS
- PSTV N/A
- COEP N/A
- Revenue
- PSTV $5,725,000.00
- COEP N/A
- Revenue This Year
- PSTV $32.12
- COEP N/A
- Revenue Next Year
- PSTV N/A
- COEP N/A
- P/E Ratio
- PSTV N/A
- COEP N/A
- Revenue Growth
- PSTV 52.63
- COEP N/A
- 52 Week Low
- PSTV $0.93
- COEP $0.13
- 52 Week High
- PSTV $2.67
- COEP $0.88
- Technical
- Relative Strength Index (RSI)
- PSTV 31.28
- COEP 34.99
- Support Level
- PSTV $0.93
- COEP $0.13
- Resistance Level
- PSTV $1.37
- COEP $0.24
- Average True Range (ATR)
- PSTV 0.11
- COEP 0.03
- MACD
- PSTV -0.04
- COEP -0.00
- Stochastic Oscillator
- PSTV 15.87
- COEP 9.29
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.